key pharmaceuticals limited
key pharmaceuticals limited Company Information
Company Number
04082308
Next Accounts
5 days late
Shareholders
lexon uk holdings ltd
Group Structure
View All
Industry
Dispensing chemist in specialised stores
Registered Address
18 oxleasow road, redditch, worcestershire, B98 0RE
Website
www.keypharma.co.ukkey pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KEY PHARMACEUTICALS LIMITED at £4.8m based on a Turnover of £9.4m and 0.51x industry multiple (adjusted for size and gross margin).
key pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KEY PHARMACEUTICALS LIMITED at £12.1m based on an EBITDA of £2m and a 6.13x industry multiple (adjusted for size and gross margin).
key pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KEY PHARMACEUTICALS LIMITED at £0 based on Net Assets of £-634.2k and 2.09x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Key Pharmaceuticals Limited Overview
Key Pharmaceuticals Limited is a live company located in worcestershire, B98 0RE with a Companies House number of 04082308. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in October 2000, it's largest shareholder is lexon uk holdings ltd with a 100% stake. Key Pharmaceuticals Limited is a mature, mid sized company, Pomanda has estimated its turnover at £9.4m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Key Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Key Pharmaceuticals Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 4 areas for improvement. Company Health Check FAQs
3 Strong
4 Regular
4 Weak
Size
annual sales of £9.4m, make it smaller than the average company (£11.9m)
£9.4m - Key Pharmaceuticals Limited
£11.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 105%, show it is growing at a faster rate (6.5%)
105% - Key Pharmaceuticals Limited
6.5% - Industry AVG
Production
with a gross margin of 43.5%, this company has a lower cost of product (32.3%)
43.5% - Key Pharmaceuticals Limited
32.3% - Industry AVG
Profitability
an operating margin of 13.1% make it more profitable than the average company (2.9%)
13.1% - Key Pharmaceuticals Limited
2.9% - Industry AVG
Employees
with 66 employees, this is similar to the industry average (75)
- Key Pharmaceuticals Limited
75 - Industry AVG
Pay Structure
on an average salary of £25.6k, the company has an equivalent pay structure (£25.6k)
- Key Pharmaceuticals Limited
£25.6k - Industry AVG
Efficiency
resulting in sales per employee of £141.8k, this is equally as efficient (£143.9k)
- Key Pharmaceuticals Limited
£143.9k - Industry AVG
Debtor Days
it gets paid by customers after 25 days, this is near the average (30 days)
25 days - Key Pharmaceuticals Limited
30 days - Industry AVG
Creditor Days
its suppliers are paid after 32 days, this is quicker than average (65 days)
32 days - Key Pharmaceuticals Limited
65 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Key Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (14 weeks)
2 weeks - Key Pharmaceuticals Limited
14 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 109.3%, this is a higher level of debt than the average (58.3%)
109.3% - Key Pharmaceuticals Limited
58.3% - Industry AVG
KEY PHARMACEUTICALS LIMITED financials
Key Pharmaceuticals Limited's latest turnover from June 2023 is £9.4 million and the company has net assets of -£634.2 thousand. According to their latest financial statements, we estimate that Key Pharmaceuticals Limited has 66 employees and maintains cash reserves of £327.9 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 9,355,650 | 4,065,780 | 3,808,731 | 1,079,562 | 2,730,230 | |||||||||
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | 5,289,155 | 2,627,913 | 2,279,762 | 68,956 | 793,592 | |||||||||
| Gross Profit | 4,066,495 | 1,437,867 | 1,528,969 | 1,010,606 | 1,936,638 | |||||||||
| Admin Expenses | 2,840,791 | 1,700,842 | 1,811,037 | 1,447,278 | 536,830 | |||||||||
| Operating Profit | 1,225,704 | -262,975 | -282,068 | -436,672 | 1,399,808 | |||||||||
| Interest Payable | 2,604 | |||||||||||||
| Interest Receivable | 2,965 | 5,443 | ||||||||||||
| Pre-Tax Profit | 1,225,704 | -262,975 | -282,068 | -433,707 | 1,402,647 | |||||||||
| Tax | -183,467 | -437,438 | -792,088 | 65,349 | -113,714 | |||||||||
| Profit After Tax | 1,042,237 | -700,413 | -1,074,156 | -368,358 | 1,288,933 | |||||||||
| Dividends Paid | 1,796,475 | 4,000 | ||||||||||||
| Retained Profit | 1,042,237 | -700,413 | -1,074,156 | -2,164,833 | 1,284,933 | |||||||||
| Employee Costs | ||||||||||||||
| Number Of Employees | 6 | 6 | 5 | 41 | 40 | |||||||||
| EBITDA* | 1,973,566 | 165,722 | 180,152 | -433,019 | 1,417,129 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 10,951 | 13,172 | 14,560 | 14,560 | 18,213 | 395,222 | 422,089 | 431,894 | 457,151 | 380,636 | 368,618 | 388,705 | 402,887 | 399,893 |
| Intangible Assets | 5,402,473 | 5,725,236 | 6,064,676 | 64,610 | 68,729 | 50,773 | 526,689 | 565,844 | 623,207 | 680,570 | 737,933 | 795,296 | 852,659 | |
| Investments & Other | 100 | |||||||||||||
| Debtors (Due After 1 year) | ||||||||||||||
| Total Fixed Assets | 5,413,424 | 5,738,408 | 6,079,236 | 14,560 | 82,923 | 463,951 | 472,862 | 958,583 | 1,022,995 | 1,003,843 | 1,049,188 | 1,126,638 | 1,198,183 | 1,252,552 |
| Stock & work in progress | 386,266 | 184,082 | 181,605 | 183,582 | 173,672 | 166,839 | 169,474 | 172,392 | 203,828 | 177,514 | ||||
| Trade Debtors | 661,218 | 186,230 | 193,897 | 157,256 | 334,573 | 721,388 | 391,257 | 293,381 | 338,649 | 309,638 | 407,412 | 391,469 | 427,930 | 268,944 |
| Group Debtors | 265,082 | 93,136 | 251,035 | |||||||||||
| Misc Debtors | 175,900 | 95,896 | 282,477 | 161,484 | 567,216 | 227,082 | 87,046 | 111,424 | ||||||
| Cash | 327,861 | 142,414 | 20,970 | 119,990 | 1,425,253 | 337,138 | 632,939 | 622,928 | 337,781 | 519,310 | 557,372 | 292,020 | 347,365 | 463,138 |
| misc current assets | ||||||||||||||
| total current assets | 1,430,061 | 517,676 | 497,344 | 824,996 | 2,578,077 | 1,469,690 | 1,292,847 | 1,211,315 | 850,102 | 995,787 | 1,134,258 | 855,881 | 979,123 | 909,596 |
| total assets | 6,843,485 | 6,256,084 | 6,576,580 | 839,556 | 2,661,000 | 1,933,641 | 1,765,709 | 2,169,898 | 1,873,097 | 1,999,630 | 2,183,446 | 1,982,519 | 2,177,306 | 2,162,148 |
| Bank overdraft | ||||||||||||||
| Bank loan | 60,469 | |||||||||||||
| Trade Creditors | 465,692 | 124,341 | 186,800 | 344,215 | 275,005 | 601,442 | 518,216 | 671,311 | 878,240 | 1,193,704 | 1,456,886 | 1,237,225 | 1,352,579 | 1,233,941 |
| Group/Directors Accounts | 5,248,501 | 6,647,175 | 6,426,418 | 320,588 | 105,638 | 93,711 | 139,600 | |||||||
| other short term finances | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| other current liabilities | 915,597 | 100,113 | 283,908 | 76,576 | 122,985 | 25,484 | 424,484 | 19,619 | ||||||
| total current liabilities | 6,629,790 | 6,871,629 | 6,897,126 | 741,379 | 397,990 | 732,564 | 1,036,411 | 890,999 | 878,240 | 1,193,704 | 1,456,886 | 1,237,225 | 1,352,579 | 1,233,941 |
| loans | 634,869 | 814,625 | 992,235 | |||||||||||
| hp & lease commitments | ||||||||||||||
| Accruals and Deferred Income | ||||||||||||||
| other liabilities | 223,000 | 223,000 | 223,000 | 279,251 | 344,835 | 508,905 | 75,000 | |||||||
| provisions | 847,850 | 1,060,847 | 655,433 | 128,875 | ||||||||||
| total long term liabilities | 847,850 | 1,060,847 | 655,433 | 223,000 | 351,875 | 223,000 | 279,251 | 344,835 | 508,905 | 709,869 | 814,625 | 992,235 | ||
| total liabilities | 7,477,640 | 7,932,476 | 7,552,559 | 741,379 | 397,990 | 955,564 | 1,388,286 | 1,113,999 | 1,157,491 | 1,538,539 | 1,965,791 | 1,947,094 | 2,167,204 | 2,226,176 |
| net assets | -634,155 | -1,676,392 | -975,979 | 98,177 | 2,263,010 | 978,077 | 377,423 | 1,055,899 | 715,606 | 461,091 | 217,655 | 35,425 | 10,102 | -64,028 |
| total shareholders funds | -634,155 | -1,676,392 | -975,979 | 98,177 | 2,263,010 | 978,077 | 377,423 | 1,055,899 | 715,606 | 461,091 | 217,655 | 35,425 | 10,102 | -64,028 |
| Jun 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 1,225,704 | -262,975 | -282,068 | -436,672 | 1,399,808 | |||||||||
| Depreciation | 3,382 | 3,156 | 3,204 | 3,653 | 13,202 | 7,044 | 515,526 | 33,024 | 28,187 | 21,063 | 24,136 | 27,487 | 29,361 | 26,941 |
| Amortisation | 744,480 | 425,541 | 459,016 | 4,119 | 29,076 | 515,526 | 60,300 | 57,363 | 57,363 | 57,363 | 57,363 | 57,363 | 57,363 | |
| Tax | -183,467 | -437,438 | -792,088 | 65,349 | -113,714 | |||||||||
| Stock | -386,266 | 386,266 | -184,082 | 2,477 | -1,977 | 9,910 | 6,833 | -2,635 | -2,918 | -31,436 | 26,314 | 177,514 | ||
| Debtors | 726,938 | -101,112 | 157,634 | -834,084 | 204,354 | 470,167 | 73,498 | 66,156 | 29,011 | -97,774 | 15,943 | -36,461 | 158,986 | 268,944 |
| Creditors | 341,351 | -62,459 | -157,415 | 69,210 | -326,437 | 83,226 | -153,095 | -206,929 | -315,464 | -263,182 | 219,661 | -115,354 | 118,638 | 1,233,941 |
| Accruals and Deferred Income | 815,484 | -183,795 | 207,332 | -46,409 | 97,501 | -399,000 | 404,865 | 19,619 | ||||||
| Deferred Taxes & Provisions | -212,997 | 405,414 | 655,433 | -128,875 | 128,875 | |||||||||
| Cash flow from operations | 2,006,999 | -11,444 | 322,046 | 102,949 | 1,054,207 | |||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | -100 | 100 | ||||||||||||
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | -60,469 | 60,469 | ||||||||||||
| Group/Directors Accounts | -1,398,674 | 220,757 | 6,105,830 | 320,588 | -105,638 | 11,927 | -45,889 | 139,600 | ||||||
| Other Short Term Loans | ||||||||||||||
| Long term loans | -634,869 | -179,756 | -177,610 | 992,235 | ||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||||
| other long term liabilities | -223,000 | -56,251 | -65,584 | -164,070 | 433,905 | 75,000 | ||||||||
| share issue | ||||||||||||||
| interest | 2,965 | 2,839 | ||||||||||||
| cash flow from financing | -1,398,674 | 220,757 | 6,105,830 | 323,553 | -325,799 | |||||||||
| cash and cash equivalents | ||||||||||||||
| cash | 185,447 | 121,444 | -99,020 | -1,305,263 | 1,088,115 | -295,801 | 10,011 | 285,147 | -181,529 | -38,062 | 265,352 | -55,345 | -115,773 | 463,138 |
| overdraft | ||||||||||||||
| change in cash | 185,447 | 121,444 | -99,020 | -1,305,263 | 1,088,115 | -295,801 | 10,011 | 285,147 | -181,529 | -38,062 | 265,352 | -55,345 | -115,773 | 463,138 |
key pharmaceuticals limited Credit Report and Business Information
Key Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for key pharmaceuticals limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in B98 area or any other competitors across 12 key performance metrics.
key pharmaceuticals limited Ownership
KEY PHARMACEUTICALS LIMITED group structure
Key Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
BESTWAY GROUP LTD
#0150716
2 parents
KEY PHARMACEUTICALS LIMITED
04082308
key pharmaceuticals limited directors
Key Pharmaceuticals Limited currently has 2 directors. The longest serving directors include Mr Gregory Pateras (Sep 2024) and Mr Thorsten Beer (Oct 2024).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Gregory Pateras | England | 48 years | Sep 2024 | - | Director |
| Mr Thorsten Beer | England | 53 years | Oct 2024 | - | Director |
P&L
June 2023turnover
9.4m
+130%
operating profit
1.2m
-566%
gross margin
43.5%
+22.91%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2023net assets
-634.2k
-0.62%
total assets
6.8m
+0.09%
cash
327.9k
+1.3%
net assets
Total assets minus all liabilities
key pharmaceuticals limited company details
company number
04082308
Type
Private limited with Share Capital
industry
47730 - Dispensing chemist in specialised stores
incorporation date
October 2000
age
25
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
June 2023
previous names
N/A
accountant
-
auditor
MAZARS LLP
address
18 oxleasow road, redditch, worcestershire, B98 0RE
Bank
-
Legal Advisor
-
key pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 14 charges/mortgages relating to key pharmaceuticals limited. Currently there are 1 open charges and 13 have been satisfied in the past.
key pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for KEY PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
key pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
